Qualitative interviews to understand health care providers' experiences of prescribing licensed peanut oral immunotherapy.

ABSTRACT:

Objective

This research sought to explore health care providers' (HCPs) experiences of delivering the first US Food and Drug Administration (FDA) and European Commission (EC) approved peanut oral immunotherapy (peanut OIT; Palforzia). Semi-structured qualitative interviews with HCPs who had initiated treatment with ≥ 3 patients in the first nine months following FDA approval sought to identify challenges faced and successful implementation strategies.

Results

Eight allergists and three nurse practitioners from eight sites based in the United States participated. The HCPs included in this research were motivated to implement this novel treatment, however, entered the process with some reservations. HCPs described how successful implementation of peanut OIT requires them to be

SUBMITTER: Anagnostou A 

PROVIDER: S-EPMC9358114 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature